Tesamorelin: The FDA-Approved Growth Hormone Peptide That Targets Visceral Fat

Tesamorelin is the one growth hormone peptide here with an FDA approval behind it, large phase 3 trials, and an effect that is unusually specific about where it acts. It shrinks the deep visceral fat around your organs, the metabolically dangerous kind, more than it touches fat elsewhere.

That makes it the best-evidenced peptide in this category. Whether it is the right one for you is a separate question from whether it works, and the answer turns on what you are actually trying to shift.

What Is Tesamorelin?

Tesamorelin is a stabilized analog of growth hormone releasing hormone (GHRH). Like sermorelin, it prompts your own pituitary to release growth hormone rather than injecting synthetic HGH. The difference is that tesamorelin was developed and studied as a pharmaceutical, and it is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in people with HIV-associated lipodystrophy.

It belongs to the same GHRH-analog family as sermorelin and CJC-1295, but it is the member with formal approval and the strongest human outcome data.

How Tesamorelin Works

Tesamorelin binds the GHRH receptor on the pituitary, stimulating a natural, pulsatile release of growth hormone, which in turn raises IGF-1 [3]. The elevated growth hormone signal preferentially mobilizes visceral adipose tissue, the deep fat packed around the abdominal organs, which is the fat most strongly linked to metabolic and cardiovascular risk.

Because it works through your own feedback-controlled release rather than flooding the body with external hormone, it keeps GH secretion in a more physiologic pattern than direct HGH would. The headline effect is not general weight loss, it is a shift in where fat is lost, specifically off the visceral compartment.

What the Evidence Actually Shows

This is where tesamorelin separates itself from most peptides. It has large, randomized, placebo-controlled trials published in top journals.

The Landmark Trial

In a randomized trial of 412 patients with HIV and abdominal fat accumulation, daily tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent over 26 weeks compared with placebo, while sparing the subcutaneous fat under the skin, and it did so without significant disruption of blood sugar [1]. That selective reduction of deep belly fat is the effect tesamorelin is known for.

Visceral Fat and Liver Fat

A later randomized clinical trial confirmed and extended the finding: tesamorelin reduced visceral fat and also lowered liver fat, which is relevant to non-alcoholic fatty liver disease, in patients with HIV and abdominal fat accumulation [2]. Reducing liver fat is a meaningful metabolic outcome, not just a cosmetic one.

The Honest Boundary

The pivotal trials were done in people with HIV-associated lipodystrophy, which is the approved indication. Interest in tesamorelin for visceral fat and fatty liver in people without HIV is growing and biologically reasonable, but using it in that broader population is off-label and less studied. That is worth knowing going in.

Tesamorelin vs Other GH Peptides

In short, tesamorelin is the GHRH analog with the best evidence and a specific, proven effect on visceral fat, but it is dosed daily and studied in a specific population. For the broader single-peptide and stack options, see our sermorelin guide and ipamorelin and CJC-1295 guide.

Dosing and Administration

In the trials, tesamorelin was given as a 2 mg subcutaneous injection once daily [1]. It is typically injected in the evening to align with the body's natural overnight growth hormone pulse, and rotated across injection sites on the abdomen. Unlike the long-acting CJC-1295, tesamorelin is short-acting, which is why it is a daily injection. The specific dose and schedule should always be set and monitored by your prescriber.

Side Effects and Safety

Tesamorelin's side effect profile is well characterized from its trials. Most effects are mild, but because it raises growth hormone, it needs medical oversight and periodic lab monitoring:

• Injection site reactions (redness, itching, swelling), the most common
• Joint pain or stiffness (arthralgia)
• Fluid retention, swelling, or tingling in the hands (from the GH effect)
• Muscle aches
• Effects on blood sugar and insulin sensitivity, which is why glucose is monitored, especially in people with or at risk of diabetes

Who Should Avoid It?

• Anyone with active malignancy (growth hormone and IGF-1 can promote cell proliferation)
• Pregnant or breastfeeding individuals
• People with disruption of the hypothalamic-pituitary axis (for example after pituitary surgery or radiation), unless managed by their specialist
• Poorly controlled diabetes, without careful monitoring, given the glucose effects

Regulatory Status

Tesamorelin (Egrifta) is FDA-approved specifically for reducing excess abdominal fat in HIV-associated lipodystrophy. Use for visceral fat, fatty liver, or body composition outside that indication is off-label and should be a careful, physician-supervised decision. When accessed through a 503A compounding pharmacy, it should always come from a properly licensed source, never from research-chemical suppliers where purity and potency are unverified. Athletes subject to testing should note that GHRH analogs are prohibited in sport.

Frequently Asked Questions

Does tesamorelin cause general weight loss?

Not exactly. Its proven, distinctive effect is reducing visceral fat, the deep fat around the organs, rather than driving large drops on the scale [1]. The value is in where the fat comes off, which is the metabolically important location, plus its effect on liver fat [2].

How is it different from sermorelin?

Both are GHRH analogs that stimulate your own growth hormone, but tesamorelin is FDA-approved, backed by large phase 3 trials, and specifically shown to cut visceral fat. Sermorelin is used more broadly for age-related GH decline with a smaller, older evidence base. See the sermorelin guide for that comparison.

How long until it works?

The trials measured visceral fat changes over about 26 weeks [1]. This is a gradual, months-long therapy, not an overnight one, and it works best alongside nutrition and activity.

Is it safer than HGH?

Because it works through your body's own feedback-controlled release rather than flooding the system with external hormone, its GH signal stays more physiologic than direct HGH. It still raises growth hormone, so it requires physician supervision and glucose monitoring. Neither is risk-free.

Bottom Line

Tesamorelin is the most rigorously validated peptide in the growth hormone category. It is FDA-approved, backed by large randomized trials, and has a specific, proven effect: reducing the deep visceral fat that matters most for metabolic health, along with liver fat [1][2]. The main caveats are that it is dosed daily, its pivotal evidence is in HIV-associated lipodystrophy, and broader use is off-label.

This article is educational, not medical advice. For the right patient, under a physician who sets the dose, monitors glucose and IGF-1, screens for the conditions where it is unsafe, and sources it from a licensed pharmacy, tesamorelin is one of the few peptides whose signature benefit is backed by the kind of evidence usually reserved for approved drugs.